Premium
New therapy with XLQ ® to suppress chronic prostatitis through its anti‐inflammatory and antioxidative activities
Author(s) -
Yang Feiya,
Meng Lingquan,
Han Panpan,
Chen Dexi,
Wang Mingshuai,
Jiang Yongguang,
Wu Yanqiao,
Wu Yiling,
Xing Nianzeng
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28380
Subject(s) - prostatitis , malondialdehyde , proinflammatory cytokine , superoxide dismutase , lipid peroxidation , medicine , glutathione peroxidase , immunology , monocyte , prostate , oxidative stress , inflammation , endocrinology , cancer
Chronic prostatitis is a common urological disease. The etiology of this disease and effective therapy for its treatment are yet to be elucidated. We investigated the functions of XLQ ® in chronic nonbacterial prostatitis using a complete Freund's adjuvant‐induced rat model. Prostates and blood samples were collected for further evaluation after oral gavage with XLQ ® or a vehicle for 4 weeks. The results showed that XLQ ® significantly decreased the prostate index, ameliorated the histopathologic changes, and reduced CD3+ and CD45+ cell infiltration in the prostate stroma. Further study showed that XLQ ® suppressed the expression of proinflammatory cytokines, such as interleukin (IL)‐1β, IL‐2, IL‐6, IL‐17A, monocyte chemoattractant protein‐1, and tumor necrosis factor‐α. XLQ ® showed a strong antioxidant capacity by enhancing the activities of antioxidative enzymes (e.g., total superoxide dismutase, catalase, and glutathione peroxidase) and decreasing the level of lipid peroxidation products (malondialdehyde). Moreover, XLQ ® can suppress the activation of nuclear factor‐κB and P38‐mitogen‐activated protein kinase signaling pathways. In summary, XLQ ® has affirmative effects on chronic prostatitis, which could be attributed to its anti‐inflammatory and antioxidative capacities. On the basis of these results, XLQ ® can be developed as an effective and safe therapy for chronic prostatitis.